Systematic review revealed deep vein thrombosis incidence of 10.4% in ICU patients, indicating distinct risk factors like catheterization and malignancy.
Deep vein thrombosis (DVT) is a frequent and often silent complication in intensive care unit (ICU) patients, markedly increasing the risk of pulmonary embolism and death. However, comprehensive quantitative evidence on ICU-DVT incidence and associated risk factors remains scarce. To synthesize global data on the epidemiology of ICU-DVT and identify independent risk factors, providing a basis for evidence-based, risk-stratified prevention. We systematically searched PubMed, Embase, Cochrane Library, and Web of Science to July 2024 for observational studies reporting ICU-DVT incidence and risk factors. Pooled odds ratios (ORs) were calculated using random-effects models (PROSPERO ID: CRD42024583844). A total of 186 studies were included, involving 203,880 ICU patients. The overall incidence of DVT was 10.4% (95% CI 8.9%-12.0%). The incidence was significantly higher in COVID-19 patients than in non-COVID-19 patients (12.4% vs. 8.4%, p < 0.01). Medical ICUs had the highest incidence (16.3%), followed by trauma ICUs (11.6%), general ICUs (10.1%), neuro ICUs (8.6%), and surgical ICUs (7.9%). The incidence varied by region (Asia 12.5%, Europe 11.8%; America 9.3%, Oceania 9.1%). Systematic screening significantly improved DVT detection rates compared with clinically suspected diagnosis (14.6% vs. 7.9%). Meta-analysis revealed that central venous catheterization, a history of DVT, use of vasoactive agents, mechanical ventilation, prolonged ICU stay, and malignancy were associated with increased DVT odds. ICU-DVT affects approximately 1 in 10 patients and is associated with distinct modifiable and non-modifiable risk factors. The influence of diagnostic strategies on DVT incidence underscores the necessity for standardized screening in the ICU. Future prospective, large-scale studies are warranted to validate causal relationships and enable the development of risk prediction tools for precision prevention.
No takes yet. Share an insight, caveat, or question.
Zuo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: